1. The use of omalizumab for treatment‐refractory chronic spontaneous urticaria in a West Australian outpatient cohort
- Author
-
Brittany Stevenson, Georgia Farrah, Katie Lie, and Anna Brusch
- Subjects
Adult ,Male ,medicine.medical_specialty ,Omalizumab ,030204 cardiovascular system & hematology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Overall response rate ,Internal medicine ,Anti-Allergic Agents ,Internal Medicine ,medicine ,Humans ,Chronic Urticaria ,In patient ,030212 general & internal medicine ,Aged ,Retrospective Studies ,Treatment refractory ,business.industry ,Remission Induction ,Retrospective cohort study ,Western Australia ,Middle Aged ,Disease control ,Treatment Outcome ,Retreatment ,Cohort ,Female ,Sustained remission ,business ,medicine.drug - Abstract
There is a lack of real-world data on the use of omalizumab in treatment-refractory chronic spontaneous urticaria (CSU). A single-centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment-refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment-resistant CSU.
- Published
- 2019
- Full Text
- View/download PDF